Maxim Group Reiterates Hold Rating for NeuroSense Therapeutics (NASDAQ:NRSN)

Maxim Group restated their hold rating on shares of NeuroSense Therapeutics (NASDAQ:NRSN) in a research report sent to investors on Monday,Benzinga reports.

NeuroSense Therapeutics Trading Up 2.8 %

NRSN stock opened at $0.88 on Monday. The firm has a 50 day moving average of $1.12 and a 200-day moving average of $1.03. The firm has a market capitalization of $12.08 million, a P/E ratio of -1.04 and a beta of 1.38. NeuroSense Therapeutics has a 12 month low of $0.51 and a 12 month high of $2.33.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in NeuroSense Therapeutics stock. XTX Topco Ltd boosted its position in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) by 40.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,996 shares of the company’s stock after buying an additional 13,346 shares during the quarter. XTX Topco Ltd owned approximately 0.34% of NeuroSense Therapeutics worth $58,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 1.04% of the company’s stock.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.